Regeneron Pharmaceuticals buys Sanofi's rights to cemiplimab, a joint drug with the trade name Libtayo. Cemiplimab is a PD-1 inhibitor for cancer immunotherapy. Sanofi will receive $900 million and a royalty of 11% of net sales. In addition, the company will be entitled to $100 million after FDA or EC approval of the drug as first-line therapy for non-small cell lung cancer in combination with chemotherapy, and up to another $100 million depending on sales volume over the next 2 years. The deal is scheduled to close in Q3 2022.
Regeneron Pharmaceuticals buys Sanofi's rights to cemiplimab, a joint drug with the trade name Libtayo. Cemiplimab is a PD-1 inhibitor for cancer immunotherapy. Sanofi will receive $900 million and a royalty of 11% of net sales. In addition, the company will be entitled to $100 million after FDA or EC approval of the drug as first-line therapy for non-small cell lung cancer in combination with chemotherapy, and up to another $100 million depending on sales volume over the next 2 years. The deal is scheduled to close in Q3 2022. 
investor.regeneron.com
English (US) 